Length140 pages

Date Published
September 2010 

Print copies are available upon request. Call 781-972-5444. 

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 



Diabetes Pipeline: Intense Activity to Meet Unmet Need Report - Table of Contents

Author: Peter Norman, MBA, PhD

CHAPTER 1
INTRODUCTION 
1.1. What is Diabetes? 
Type I Diabetes 
Type II Diabetes 
1.2. Diabetic Complications
1.3. The Need for Improved Disease Control 

CHAPTER 2
DIABETES 
2.1. Pathophysiology 
2.2. Diagnosis 
2.3. Incidence and Prevalence 

Gestational Diabetes 
Early Onset Diabetes 
Metabolic Syndrome 
Other Causes of Diabetes 
2.4. Current Treatment Options 

CHAPTER 3
CURRENTLY MARKETED THERAPIES 
3.1. Introduction 
3.2. Insulin 
Recombinant Insulins 
Insulin Analogs 
3.3. Metformin 
3.4. KATP Blockers 
Sulfonylureas 
Non-Sulfonylureas 
3.5. PPAR Agonists 
3.6. Alpha−Glucosidase Inhibitors 
3.7. Incretin Modulators 
Peptide Agonists 
DPP IV Inhibitors 
3.8. Combination Products 
3.9. Market Breakdown 

CHAPTER 4
DEVELOPMENT PIPELINES 
4.1. Introduction 
4.2. Established Approaches 

Insulin, Analogs, and Formulations 
Pharmacodynamic Approaches for Improved Control of Plasma Insulin 
Fast Release 
VIAject 
Long Acting 
Degludec 
FT-105 
Sustained Control 
Degludec Plus 
LY-2605541  
Alternative Delivery Routes for Insulin 
Inhaled 
Afrezza 
Intranasal 
Oral 
Oral-lyn 
IN-105  
AI-401 
Transdermal 
Absorption Enhancing 
PPAR Agonists 
PPARγ Agonists 
PPARδ Agonists 
Dual PPAR α/γ Agonists 
Indeglitazar: A Pan-PPAR Agonist 
Other, Non-Incretin, Approaches 
Mitiglinide 
Avandastat 
Imeglimin 
GLP-1 Analogs 
Exenatide Formulation 
Bydureon 
Novel GLP-1 Analogs 
Taspoglutide  
Lixisenatide 
Albiglutide  
Dulaglutide  
Other GLP-1 Agonists in Clinical Development  
GLP-1 Modulator 
DPP IV Inhibitors 
Phase III DPP IV Inhibitors 
Linagliptin  
Dutogliptin  
SK-0403 
Teneligliptin  
Gemigliptin  
Phase II DPP IV Inhibitors 
4.3. New Approaches 
SGLT2 Inhibition 
Dapagliflozin  
Canagliflozin 
 ASP-1941 
BI-10773 and BI-44847 
RG-7201 
LX-4211  
TS-071 
ISIS-388626 
Kissei, GlaxoSmithKline SGLT Inhibitors 
Glucokinase Activators 
AZD-1656 and AZD-6370 
LY-2599506  
AMG-151  
TTP-355 and TTP-399 
Phase I Compounds 
11β-Hydroxysteroid Dehydrogenase 1 Inhibitors 
INCB-13739  
Roche 
JTT-654  
AstraZeneca 
HSD-016 
Amgen 
PTP1B Inhibitors 
ISIS-113715 
TransTech Pharma’s TTP-814 
GPR119 Agonists 
FFA1 Agonists 
DGAT-1 Inhibitors 
SCD1 Inhibitors 
GPBA Agonists 
Fructose Bisphosphatase Inhibitors 
Glycogen Phosphorylase Inhibitors 
AMPKa Modulators  
SIRT1 Activators 
Other Oral Agents 
D-Tagatose 
Phase II Agents 
Phase I Agents 
Biological Agents 
Anti-CD3 Antibodies 
Teplizumab 
Otelixizumab 
DiaPep277 
Diamyd’s Vaccines 
IL-1 Antagonists 
Bayhill Therapeutics/Genentech’s RG-7426 

CHAPTER 5
COMPANY PROFILES 
5.1. Introduction 
5.2. Major Players 
Eli Lilly 
GlaxoSmithKline 
Merck 
Novo Nordisk 
sanofi-aventis 
Takeda 
5.3. Emerging Players 
Amgen 
Astellas 
AstraZeneca 
Boehringer Ingelheim 
Bristol-Myers Squibb 
Novartis 
Pfizer 
Roche 
5.4. Specialist Companies 
Amylin 
Arisaph Pharmaceuticals 
Biodel 
DARA BioSciences 
Diabetology 
DiaMedica 
Diasome Pharmaceuticals 
Ipsen 
Lexicon Therapeutics 
Metabolex 
Phenomix 
Piramal Life Sciences 
Poxel 
Syndexa Pharmaceuticals 
Theracos 
TransTech Pharma 

CHAPTER 6
MARKET OUTLOOK 
6.1. Introduction 
6.2. The Impact of Generics
6.3. The Impact of New Therapies 
Injectable Agents 
Oral Agents 
6.4. Market Development 

CHAPTER 7
EXPERT INTERVIEWS 

Peter Kurtzhals, PhD
Senior Vice President and Head of Diabetes Research
Novo Nordisk  
Pascale Malgouyres, PharmD
Business Development and Marketing Director
Poxel  
Harold E. Van Wart, PhD
President and Chief Executive Officer
Metabolex  
Type I Diabetes  
Type II Diabetes 

REFERENCES 

GLOSSARY 

COMPANY INDEX